Resources

Resources for your practice

An image of the front cover of the AOM Phenotype Trial in Obesity brochure.

AOM Phenotype Trial in Obesity Brochure

Learn how an individualized approach to selecting antiobesity medications (AOMs) could help your patients.1

Download
An image of the front cover of the Mysimba® Overview Brochure that uses the updated imagery of a woman running on the beach.

Mysimba® Overview Brochure

Learn about Mysimba®-from efficacy and safety to why it may be the right treatment for your patients seeking weight loss who struggle with emotional eating.

Download
An image of the patient profiles tool that features the branded brain campaign with a side-profile silhouette of a woman and text written where the brain is.

Mysimba® Patient Profiles

Meet 2 patients seeking weight loss and struggling with emotional eating who both may benefit from Mysimba®, and learn how you can identify similar patients in your practice.

Download
Savings and Support Guide

CurAccess Program Instructions

See how the CurAccess Patient Support Program can help your patients save.

Download
An image of the front cover of the ICD-10 Reference Guide.

ICD-10 Reference Guide

A list of common obesity-related ICD-10 codes to reference for billing and insurance processing for appropriate patients.

Download
An image that shows the Prior Authorization (PA) checklist.

Prior Authorization
(PA) Checklist

Use this checklist to help collect the information most often needed to submit a PA for Mysimba®.

Download

References:

  1. Acosta A, Camilleri M, Dayyeh BA, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662-671. doi:10.1002/oby.23120
Reporting adverse effects: Adverse effects should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively you can report a suspected adverse drug reaction to the Yellow Card scheme by calling 0800 731 6789 Adverse events should also be reported to Orexigen®: +44 20 3966 0116 or currax.mi@primevigilance.com.
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014